Share Price
31.00 p
-0.5 (-1.59 %)
Market Cap
£14.50 m
Proactive Investors - Run By Investors For Investors


IXICO is dedicated to delivering insights in neuroscience. The company's mission is to transform the advancement of investigational therapies for neurological diseases through the application of medical image analysis and digital health technologies, bringing safe and effective treatment to patients sooner. 

IXICO’s digital platform and Artificial Intelligence (AI) software are used by...

Market: AIM:IXI
52-week High/Low: 4,200.00p / 18.78p
Sector: Pharma & Biotech
Market Cap: 14.50M
Website: www.ixico.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of IXICO PLC

IXICO PLC Timeline

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes

IXICO bags a £1mln contract

Huntingdon's Disease is a rare genetic neurodegenerative disorder that affects movement, cognition and behaviour. This is an area of significant unmet medical need.
IXICO's analysis technology is being used by a US biopharma for a phase II trial of a new treatment for Huntington’s disease and by a different company for a Phase II/III clinical trial contract in Alzheimer's disease; the scope of both contracts has been extended

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use